Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
429.82
+4.82 (1.13%)
At close: May 8, 2026, 4:00 PM EDT
429.00
-0.82 (-0.19%)
After-hours: May 8, 2026, 7:19 PM EDT
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,400 employees as of December 31, 2025. The number of employees increased by 300 or 4.92% compared to the previous year.
Employees
6,400
Change (1Y)
300
Growth (1Y)
4.92%
Revenue / Employee
$1,909,063
Profits / Employee
$677,859
Market Cap
109.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,400 | 300 | 4.92% |
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,863 |
| Insmed | 1,664 |
VRTX News
- 3 days ago - Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays - TheFly
- 3 days ago - Vertex Pharmaceuticals announces Casgevy reimbursement agreement - TheFly
- 4 days ago - Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany - Business Wire
- 5 days ago - Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley - TheFly
- 5 days ago - Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital - TheFly
- 5 days ago - Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord - TheFly
- 5 days ago - Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein - TheFly
- 5 days ago - Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals - TheFly